TOPICAL RETINALDEHYDE ON HUMAN SKIN - BIOLOGIC EFFECTS AND TOLERANCE

被引:100
作者
SAURAT, JH
DIDIERJEAN, L
MASGRAU, E
PILETTA, PA
JACONI, S
CHATELLARDGRUAZ, D
GUMOWSKI, D
MASOUYE, I
SALOMON, D
SIEGENTHALER, G
机构
[1] Department of Dermatology, University Hospital, Geneva
关键词
RETINOIC ACID; 9 CIS RETINOIC ACID; CELLULAR RETINOID BINDING PROTEINS; RETINOL; BETA CAROTENE;
D O I
10.1111/1523-1747.ep12412861
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The present study was designed to explore retinaldehyde, a natural metabolite of vitamin A, has any biologic activity and is tolerated by human skin. Biologic activity was shown by the induction of cellular retinoic acid-binding protein type 2 (CRABP 2) mRNA and protein; the rank order for CRABP-2 increase was retinoic acid > retinaldehyde > 9 cis retinoic acid > retinol > beta carotene. In volunteers treated 1-3 months with 0.5, 0.1, and 0.05% retinaldehyde, there was a dose-dependent and significant increase in epidermal thickness, keratin 14 immunoreactivity, and Ki67-positive cells. The area of distribution of involucrin, transglutaminase, and filaggrin immunoreactivity was also increased in a dose-dependent manner, and keratin 4 immunoreactivity was induced in the upper epidermis. In pilot clinical tolerance studies, 229 patients received topical retinaldehyde at different concentrations; the 1% preparation was tolerated by up to 70% of the treated subjects; tolerance of the 0.5% preparation was slightly better, whereas both 0.1 and 0.05% preparations applied on facial skin were well tolerated and allowed prolonged use (up to 3 years) in patients with inflammatory dermatoses. These findings indicate that topical retinaldehyde has biologic activity and is well tolerated on human skin.
引用
收藏
页码:770 / 774
页数:5
相关论文
共 26 条
[11]  
Piletta P, 1994, Exp Dermatol, V3, P23, DOI 10.1111/j.1600-0625.1994.tb00262.x
[12]  
Piletta P, 1993, Exp Dermatol, V2, P191, DOI 10.1111/j.1600-0625.1993.tb00032.x
[13]  
REDFERN CPF, 1993, J INVEST DERMATOL, V101, P250
[14]   ALL-TRANS-RETINOYL IS A LIGAND FOR THE RETINOIC ACID RECEPTORS [J].
REPA, JJ ;
HANSON, KK ;
CLAGETTDAME, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (15) :7293-7297
[15]   ACUTE OR CHRONIC TOPICAL RETINOIC ACID TREATMENT OF HUMAN SKIN INVIVO ALTERS THE EXPRESSION OF EPIDERMAL TRANSGLUTAMINASE, LORICRIN, INVOLUCRIN, FILAGGRIN, AND KERATIN-6 AND KERATIN-13 BUT NOT KERATIN-1, KERATIN-10, AND KERATIN-14 [J].
ROSENTHAL, DS ;
GRIFFITHS, CEM ;
YUSPA, SH ;
ROOP, DR ;
VOORHEES, JJ .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1992, 98 (03) :343-350
[16]  
SCHOLZ SH, 1989, EUR J CLIN INVEST, V19, P220
[17]   EXPRESSION OF CRABP-I AND CRABP-II IN HUMAN EPIDERMAL-CELLS - ALTERATION OF RELATIVE PROTEIN AMOUNTS IS LINKED TO THE STATE OF DIFFERENTIATION [J].
SIEGENTHALER, G ;
TOMATIS, I ;
CHATELLARDGRUAZ, D ;
JACONI, S ;
ERIKSSON, U ;
SAURAT, JH .
BIOCHEMICAL JOURNAL, 1992, 287 :383-389
[18]  
SIEGENTHALER G, 1990, METHOD ENZYMOL, V189, P299
[19]  
SIEGENTHALER G, 1991, RETINOIDS : 10 YEARS ON, P56
[20]   OVEREXPRESSION OF CELLULAR RETINOIC ACID-BINDING PROTEIN TYPE-II (CRABP-II) AND DOWN-REGULATION OF CRABP-I IN PSORIATIC SKIN [J].
SIEGENTHALER, G ;
TOMATIS, I ;
DIDIERJEAN, L ;
JACONI, S ;
SAURAT, JH .
DERMATOLOGY, 1992, 185 (04) :251-256